Chinese late-stage clinical biopharmaceutical company Minghui Pharmaceutical announced on Friday an exclusive licensing and collaboration agreement with Qilu Pharmaceutical for the development, manufacturing and commercialisation of B7-H3 ADC (MHB088C) in Greater China (including Mainland China, Hong Kong, Macau and Taiwan).

Under the agreement, Qilu will obtain exclusive rights to MHB088C in the region and Minghui will be eligible for total payments of up to CNY1.345bn, including: CNY280m upfront and a near-term milestone payment; CNY1.065bn in development, regulatory and sales milestone payments; and up to double-digit royalties on net product sales.

Minghui will retain global rights to MHB088C outside Greater China and continue advancing its development in these regions.

MHB088C is an innovative B7-H3-targeted antibody-drug conjugate (ADC) developed using Minghui's proprietary SuperTopoi ADC platform. According to Minghui it offers potent anti-tumour activity and superior safety profile, significantly expanding the therapeutic window. Subgroup analyses in small cell lung cancer (SCLC) and metastatic castration-resistant prostate cancer (mCRPC) will be presented at the ASCO 2025 Annual Meeting.